(Pasithea) Pasithea Therapeutics has started offering Esketamine Nasal Spray for treating resistant depression in adults at its clinics in Knightsbridge, London, after approval.
Pasithea CEO Dr. Tiago Reis Marques says the approval is a significant milestone for its patients and a win for its UK clinics.
The win is significant, with Marques saying that Esketamine is highly effective and safe. He says that about 30% of patients with depression fail to respond well to the existing antidepressant treatments.
Pasithea now becomes the third clinic accredited in the UK to offer the Esketamine nasal spray.
KTTA: NASDAQ is up +14.64% on premarket.
